Loading patent…
OwnerDaniella Licht, Ioana Lovinger +6inventors
InventorsDaniella Licht, Ioana Lovinger, Suher Abd-Elhai, Mazzi Dagan-Lion, Adrian Gilbert, Noa Leibovitch, Sasson Cohen, Ruth Levy
Estimating the term…
The subject provides a sustained release tablet comprising the following components: a) a uniform admixture of an active ingredient selected from the group consisting of valproic sodium acid, a pharmaceutically acceptable salt or ester of valproic acid, divalproex sodium, valpromide and a compound having the structure: 1 wherein R1, R2, and R3 are independently the same or different and are hydrogen, a C1-C6 alkyl group, an aralkyl group, or an aryl group, and n is an integer which is greater than or equal to 0 and less than or equal to 3; and a binder, and b) a hydroxypropylmethyl cellulose, a process for manufacturing the tablet and a method of treating neuropathic pain, epilepsy, mania in bipolar disorder, a headache disorder, pain or of effecting pain prophylaxis in a subject.
A sustained release solid dosage form comprising the following components:
A sustained release solid dosage form comprising the following components:
A hard compressed tablet comprising a uniform admixture of the following components:
A composition in granulate form comprising a uniform admixture of:
A sustained release tablet comprising a compound having the structure:
A controlled release oral unit dose composition comprising N-(2-propylpentanoyl)glycinamide and at least one pharmaceutically acceptable carrier, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 24 hours after ingestion of a single oral unit dose.
A controlled release oral dose composition comprising N-(2-propylpentanoyl)glycinamide and a pharmaceutically acceptable carrier, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide of 0.5 μg/mL to 16 μg/mL per a 1000 mg dose in the composition.
A controlled release oral dose composition comprising N-(2-propylpentanoyl)glycinamide and a pharmaceutically acceptable carrier, wherein the composition when orally ingested by a human subject, induces a peak blood plasma level of N-(2-propylpentanoyl)glycine of 0.5 μg/mL to 1.7 μg/mL per a 1000 mg dose of N-(2-propylpentanoyl) glycinamide in the composition.
A method of inducing in a human subject a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 24 hours after administration of N-(2-propylpentanoyl)glycinamide, comprising administering to the human subject a controlled release oral unit dose composition comprising N-(2-propylpentanoyl)glycinamide and at least one pharmaceutically acceptable carrier, which composition induces a peak blood plasma level of N-(2-propylpentanoyl)glycinamide between 4 and 24 hours after administration of a single oral unit dose.
Dependencies are inferred from the claim text.